| Induction of Krüppel-Like Factor 5 Expression by Androgens Results in Increased CXCR4-Dependent Migration of Prostate Cancer Cells in Vitro DE Frigo, AB Sherk, BM Wittmann, JD Norris, Q Wang, JD Joseph, ... Molecular endocrinology 23 (9), 1385-1396, 2009 | 82 | 2009 |
| Benefits, challenges, critical success factors and motivations of Quality 4.0–A qualitative global study J Antony, O McDermott, M Sony, A Toner, S Bhat, EA Cudney, ... Total Quality Management & Business Excellence 34 (7-8), 827-846, 2023 | 46 | 2023 |
| The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance AP Toner, F McLaughlin, FJ Giles, FJ Sullivan, E O'connell, LA Carleton, ... British journal of cancer 109 (8), 2131-2141, 2013 | 17 | 2013 |
| Lean, Green and Sustainability: 8th IFIP WG 5.7 European Lean Educator Conference, ELEC 2022, Galway, Ireland, November 22–24, 2022, Proceedings O McDermott, A Rosa, JC Sá, A Toner Springer Nature, 2023 | | 2023 |
| Further preclinical assessment of compound EL102 in the treatment of prostate cancer. AP Toner, FJ Giles, F Sullivan, E Harte, LA Carleton, AM Gorman, J Lewis, ... Journal of Clinical Oncology 32 (15_suppl), e16053-e16053, 2014 | | 2014 |
| Preclinical assessment of the novel compound EL102 in A Toner Br J Cancer 109 (8), 2131-41, 2013 | | 2013 |
| Introducing novel toluidine sulfonamide EL102, a potential chemotherapeutic in prostate cancer A Toner, FJ Giles, FJ Sullivan, K Walsh, G Durkan, E Rogers, JD Lewis, ... BJU INTERNATIONAL 111, 61-61, 2013 | | 2013 |
| Prostate cancer inhibitory activity of a novel dual inhibitor, EL102, in combination with docetaxel, and its effects on MDR1-mediated drug resistance in vitro. SA Glynn, A Toner, J Lewis, F Sullivan, L Breen, M Clynes, FJ Giles Journal of Clinical Oncology 30 (15_suppl), e15126-e15126, 2012 | | 2012 |
| Abstract B18: EL102: A novel dual inhibitor which demonstrates additive prostate cancer inhibitory activity in combination with docetaxel in vitro and in mouse models A Toner, F McLaughlin, J McMahon, FJ Giles, F Sullivan, L Breen, ... Cancer Research 72 (4_Supplement), B18-B18, 2012 | | 2012 |
| Abstract LB-385: Pre-clinical development of the novel, broad spectrum, anti-cancer agent EL102 F McLaughlin, F McLaughlin Cancer Research 71 (8_Supplement), LB-385-LB-385, 2011 | | 2011 |
| Lean, Green and Sustainability O McDermott, A Rosa, JC Sá, A Toner | | |
